Your browser is no longer supported. Please, upgrade your browser.
Settings
ARVN Arvinas, Inc. daily Stock Chart
ARVN [NASD]
Arvinas, Inc.
Index- P/E- EPS (ttm)-5.54 Insider Own0.90% Shs Outstand69.73M Perf Week7.88%
Market Cap1.75B Forward P/E- EPS next Y-2.32 Insider Trans- Shs Float61.08M Perf Month7.88%
Income-173.10M PEG- EPS next Q-0.56 Inst Own75.90% Short Float1.14% Perf Quarter14.28%
Sales14.80M P/S118.02 EPS this Y-736.70% Inst Trans3.22% Short Ratio3.39 Perf Half Y51.73%
Book/sh3.71 P/B6.75 EPS next Y-7.90% ROA-105.40% Target Price29.50 Perf Year-
Cash/sh2.28 P/C10.98 EPS next 5Y- ROE-678.40% 52W Range10.19 - 28.25 Perf YTD94.94%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-11.33% Beta-
Dividend %- Quick Ratio7.80 Sales past 5Y- Gross Margin- 52W Low145.83% ATR1.43
Employees103 Current Ratio7.80 Sales Q/Q17.60% Oper. Margin- RSI (14)53.47 Volatility7.82% 5.80%
OptionableYes Debt/Eq0.02 EPS Q/Q25.00% Profit Margin- Rel Volume1.20 Prev Close25.21
ShortableYes LT Debt/Eq0.02 EarningsAug 14 BMO Payout- Avg Volume204.75K Price25.05
Recom2.30 SMA202.85% SMA501.30% SMA20023.29% Volume245,106 Change-0.63%
Sep-12-19Initiated BMO Capital Markets Outperform
Aug-06-19Initiated Cantor Fitzgerald Overweight $42
Jun-05-19Downgrade Citigroup Buy → Neutral $21 → $22
Apr-12-19Initiated Evercore ISI Outperform
Oct-22-18Initiated Piper Jaffray Overweight $23
Oct-22-18Initiated Goldman Neutral $17
Oct-22-18Initiated Citigroup Buy $21
Aug-27-19 07:00AM  Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader GlobeNewswire
Aug-16-19 12:46PM  David Swensen Sells DocuSign in 2nd Quarter GuruFocus.com
Aug-07-19 07:00AM  Arvinas To Present at the Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-05-19 07:00AM  Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire -7.86%
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-29-19 07:00AM  Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer GlobeNewswire
Jul-25-19 07:00AM  Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk GlobeNewswire +7.28%
Jul-18-19 07:00AM  Arvinas to Present Preclinical Tau-Directed PROTAC® Protein Degrader Data at Alzheimer's Association International Conference GlobeNewswire
Jun-27-19 06:54AM  Will Arvinas Continue to Surge Higher? Zacks
Jun-26-19 06:28PM  Is Arvinas, Inc. (ARVN) A Good Stock To Buy? Insider Monkey
Jun-25-19 07:00AM  Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer GlobeNewswire
Jun-20-19 08:30AM  Arvinas to Present at the BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-06-19 07:00AM  Arvinas to Present at the Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire
Jun-04-19 07:00AM  Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants PR Newswire +9.68%
07:00AM  Bayer and Arvinas to Collaborate on Human PROTAC® Therapies and Launch a Separate Joint Venture to Develop Agricultural PROTAC® Applications GlobeNewswire
May-29-19 07:00AM  Arvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer GlobeNewswire +5.11%
May-11-19 01:30PM  Did Hedge Funds Drop The Ball On Arvinas, Inc. (ARVN) ? Insider Monkey
May-08-19 07:00AM  Arvinas Reports First Quarter Financial Results and Provides Corporate Update GlobeNewswire +5.79%
Apr-02-19 07:00AM  Arvinas Strengthens Management Team with Internal Appointments of Andy Crew, Ph.D. as Chief Technology Officer and Ian Taylor, Ph.D. as Chief Scientific Officer GlobeNewswire +8.33%
Mar-26-19 07:00AM  Arvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-25-19 07:00AM  Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC Protein Degrader, ARV-110 GlobeNewswire
Mar-16-19 09:16AM  Did Arvinas Holding Company, LLC (NASDAQ:ARVN) Insiders Buy Up More Shares? Simply Wall St.
Feb-07-19 04:30PM  Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium GlobeNewswire
Feb-01-19 12:08PM  Protein Degradation: Finally, A Way To Treat 'Undruggable' Diseases? Investor's Business Daily
Jan-04-19 05:00PM  Arvinas Receives Authorization to Proceed for its IND Application for PROTAC Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer GlobeNewswire +6.35%
Dec-07-18 07:00PM  Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS) GlobeNewswire +5.07%
Nov-20-18 06:00AM  Arvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Oct-23-18 07:30AM  Arvinas to Present at Two Protein Degradation Conferences GlobeNewswire
Oct-03-18 08:15PM  Arvinas Inc (ARVN) President and CEO John G Houston Bought $480,000 of Shares GuruFocus.com +5.67%
Sep-27-18 10:42AM  Arvin's stock soars in its public debut, after upsized IPO priced at top of expected range MarketWatch
06:49AM  [$$] Biotech Arvinas Prices Upsized IPO at High End of Range The Wall Street Journal
Sep-26-18 08:06PM  Arvinas Announces Pricing of Initial Public Offering GlobeNewswire
Sep-22-18 04:15PM  The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers Benzinga
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has a collaboration with Bayer AG to develop novel proteolysis-targeting chimera candidates for humans and plants. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.